CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Cephalon, Inc. v. Fresenius Kabi USA, LLC

1:15-cv-00536

Overview

Case Number 1:15-cv-00536
Filing Date 2015-06-24
Status Terminated
Termination Date 2016-07-29
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Fresenius Kabi USA, LLC Operating Company

Represented By

6 Attorneys Listed

Megan C. Haney

Phillips, Goldman, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street

Lawrence M. Sung

Email: lsung@wiley.law

Karin A. Hessler

UNDELIVERABLE EMAIL 8/19/2019

Benjamin J. Schladweiler

Greenberg Traurig, LLP

Tel: +1 (302) 661-7394

The Nemours Building, 1007 North Orange Street, Suite 1200

A. Neal Seth

Email: nseth@wileyrein.com

John C. Phillips , Jr.

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St

Plaintiff

Cephalon, Inc. Operating Company

Represented By

10 Attorneys Listed

Vanessa Ribeiro Tiradentes

Gould & Ratner LLP

Tel: +1 (312) 899-1628

222 N. LaSalle Street, Suite 800

Stephanie M. Piper

Email: stephanie.piper@us.dlapiper.com

Soumitra Deka

Email: sam.deka@dlapiper.com

Sara E. Bussiere

UNDELIVERABLE EMAIL 5/28/2021

Tel: +1 (302) 655-5000

James M. Lyons

Email: james.lyons@wilmerhale.com

David M. Harris

Email: david.harris@kayescholer.com

Daniel P. DiNapoli

Email: daniel.dinapoli@apks.com

Assad H. Rajani

Email: assad.rajani@arnoldporter.com

Aaron Stiefel

Email: aaron.stiefel@apks.com

Stephen B. Brauerman

Bayard, P.A.

Tel: +1 (302) 655-5000
Fax: +1 (302) 658-6395

Bayard, P.A., 600 N. King Street

Respondent

Piyush Patel NPE (Individual / Inventor)

Represented By

0 Attorneys Listed
No attorneys available

Rachel Labell NPE (Individual / Inventor)

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 12 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (12): 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8344006
Liquid formulations of bendamustine
Filed: 2012-01-31
Issued: 2013-01-01
Active (5.2 yrs remaining)
Expires: 2032-01-31

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Active Threat

Active Threat — Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

17

Dispositive

0

Granted

0

Denied

0

Pending / Review

13

Motions by Category

Procedural / Extension Motion 6 Claim Construction / Markman Filing 11

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending
SO ORDERED, re 67 STIPULATION TO EXTEND TIME Deadline to finally supplement, inter alia, the identification of all accused products and all invalidity reference...
Entry #— • 2016-07-14
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME Deadline to finally supplement, inter alia, the identification of all accused products and all invalidity references to August 1, 201...
Entry #67 • 2016-07-08 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 65 Stipulation and Order to Extend Time filed by Cephalon, Inc. Signed by Judge Leonard P. Stark on 6/27/16. (ntl)
Entry #— • 2016-06-28
Claim Construction / Markman Filing Pending / Under Review
STIPULATION and [Proposed] Order to Extend Time for Parties to Submit their Claim Construction Briefing to August 8, 2016 by Cephalon, Inc.. (Brauerman, Stephen...
Entry #65 • 2016-06-21 Document →
Claim Construction / Markman Filing Pending / Under Review
CLAIM CONSTRUCTION OPENING BRIEF /Plaintiff Cephalon, Inc.'s Opening Claim Construction Brief filed by Cephalon, Inc.. (Brauerman, Stephen) (Entered: 06/10/2016...
Entry #55 • 2016-06-10 Document →
Claim Construction / Markman Filing Pending / Under Review
DECLARATION re 55 Claim Construction Opening Brief /Declaration of Aaron Stiefel by Cephalon, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, #...
Entry #56 • 2016-06-10 Document →

Docket Entries

(124 total)
Pleading / Complaint

COMPLAINT for Patent Infringement filed against Fresenius Kabi USA, LLC - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1745212.) - filed by Cephalon, Inc. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(klc) (Entered: 06/25/2015)

Entry #1 • 2015-06-24
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (klc) (Entered: 06/25/2015)

Entry #2 • 2015-06-24
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 5/13/2015. Date of Expiration of Patent: 9/23/2029.Thirty Month Stay Deadline: 11/13/2017. (klc) (Entered: 06/25/2015)

Entry #3 • 2015-06-24
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,344,006. (klc) (Entered: 06/25/2015)

Entry #4 • 2015-06-24
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Teva Pharmaceuticals Industries Ltd. for Cephalon, Inc. filed by Cephalon, Inc. (klc) (Entered: 06/25/2015)

Entry #5 • 2015-06-24
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc